SOLICITATION NOTICE
66 -- Optimization Slides, Reagents Kit, and Reagent Delivery Methods
- Notice Date
- 5/23/2024 9:25:55 AM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 75N95024Q00161
- Response Due
- 5/31/2024 8:00:00 AM
- Archive Date
- 06/15/2024
- Point of Contact
- Hashim Dasti, Phone: 3014028225, Karen Mahon, Phone: 3014357479
- E-Mail Address
-
hashim.dasti@nih.gov, Karen.Mahon@nih.gov
(hashim.dasti@nih.gov, Karen.Mahon@nih.gov)
- Description
- �(i)������� This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii)������� The solicitation number is 75N95024Q00161 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13�Simplified Acquisition Procedures; FAR Subpart 13.5� Simplified Procedures for Certain Commercial Items; and FAR Part 12�Acquisition of Commercial Items, and is expected to exceed the simplified acquisition threshold.� (iii)������ The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2024-04, with effective date May 1, 2024. (iv)������ The associated NAICS code 334516 � Analytical Laboratory Instrument Manufacturing and the small business size standard is 1,000 employees. This requirement is Brand Name or Equal, full and open competition. (v)������� This requirement is for the following items: � � The Contractor shall provide 10X Genomics brand-name or equal items as specified below: � �Items are required from the following categories: 3' Single Index 3' Dual Index 3' Cellplex (DI only) 5' Single Index 5' Dual Index Mutliome ATAC V2 3' HT 3' LT 5' HT Fixed Single Cell Nuclei Isolation Visium for CytAssist Xenium (vi)������ Salient Characteristics: 3' Dual Index 3' Cellplex (DI only) Salient Characteristics - The Chromium Next GEM Single Cell 3� Reagent Kits enables deep profiling of complex cell populations with high-throughput 3� digital gene expression and feature analysis of individual cells. Single-cell sequencing provides several advantages, including: Single-cell sequencing can detect biologically relevant gene expression signals masked by bulk measurement for a wide dynamic range of individual cells per chip across heterogeneous cell types (up to 8,000 cells per LT chip, up to 80,000 cells per standard throughput chip, up to 320,000 cells per HT chip) Rare or novel cell types may also be uncovered and characterized based on environmental or experimental conditions. Simultaneous assessment of many phenotypes (e.g., gene expression and protein abundance) Targeted gene expression analysis with pre-designed and custom gene panels 5' Single Index & 5' Dual Index Salient Characteristics - Chromium Next GEM Single Cell 5� The Chromium Next GEM Single Cell 5� Reagent Kits provide a scalable solution for profiling full-length paired V(D)J transcripts on a cell-by-cell basis. Delivers paired full-length T-cell and B cell receptor sequences at the single-cell level using universal and unbiased amplification strategies, thus avoiding amplification and detection bias associated with complex multiplex PCR while revealing deeper biological complexity of antigen specificity on a per-cell basis than single-chain (e.g., TCR) methods. The incorporation of a unique molecular identifier (UMI) in the template switch oligo enables transcript quantification and further reduces systematic bias by controlling for non-biological SNVs or other variants introduced by PCR and sequencing error. Enables the detection of germline and somatic variation across full-length antigen receptor V(D)J gene sequences. Identifies both productive and non-productive recombination events as well as adaptive immune cells with more than one productive T-cell receptor alpha or beta chain. Maps transcription start sites, promotor, and alternative promoter elements. Targeted gene expression analysis with pre-designed and custom gene panels Automated Automated versions of the 3� and 5� expression kits are available for runs on the Connect Multiome Salient Characteristics - Chromium Next GEM Single Cell Multiome ATAC + Gene Expression The Chromium Next GEM Single Cell Multiome ATAC + Gene Expression Reagent Kits enable simultaneous profiling of the whole transcriptome and epigenome from the same single cell 10x Genomics Sole Source Document � Rev J � Next GEM 5 Simultaneously interrogate open chromatin and 3� gene expression in up to 10,000 individual nuclei per sample (8 samples per run) Deeply characterize cell types and states with linked transcriptomic and epigenomic analysis Discovery new gene regulatory interactions Analyze high resolution paired transcriptomic and epigenetic data with turnkey software ATAC V2 Salient Characteristics - Chromium Next GEM Single Cell Multiome ATAC + Gene Expression The Chromium Next GEM Single Cell Multiome ATAC + Gene Expression Reagent Kits enable simultaneous profiling of the whole transcriptome and epigenome from the same single cell. 10x Genomics Sole Source Document Rev J � Next GEM 5 Simultaneously interrogate open chromatin and 3� gene expression in up to 10,000 individual nuclei per sample (8 samples per run) Deeply characterize cell types and states with linked transcriptomic and epigenomic analysis Discovery new gene regulatory interactions Analyze high resolution paired transcriptomic and epigenetic data with turnkey software Visium FFPE V1 & Visium FF Salient Characteristics - Formalin-Fixed Paraffin Embedded (FFPE) Sample Workflow FFPE tissues are sectioned and placed in the capture areas on the Visium Spatial Gene Expression slide. Utilizing standard H&E or immunofluorescence staining techniques, tissue sections are visualized on the slide to capture the morphological image of each section. The tissue is de-crosslinked to release mRNA that was sequestered by formalin fixation. Human or mouse whole transcriptome SAM000089, Rev B probe panels, consisting of a pair of specific probes for each targeted gene, are added to the tissue. These probe pairs hybridize to their gene target and are then ligated to one another. The ligation products are released from the tissue upon RNase treatment and permeabilization. Universal conditions for sample decrosslinking and tissue permeabilization are used; tissue specific optimization is not needed for the Visium Spatial Gene Expression Solution for FFPE tissues. For each section mounted on the Visium Spatial Gene Expression slide, ligated probe pairs from the tissue bind with spatially barcoded oligonucleotides present on the capture areas of the slide. The probe pairs are extended to incorporate complements of the spatial barcodes. The spatially barcoded, ligated probe products are released from the slide and PCR amplified. The probe products are further processed to generate an NGS-ready library. The Visium Spatial Gene Expression library is sequenced using standard short-read sequencers, and data is processed and visualized using 10x Genomics software: Space Ranger analysis pipelines and Loupe Browser visualization software. Unique Platform Characteristics 2, 4, or 16 reaction Visium Spatial Gene Expression kits available All critical and non-standard reagents and slides are included in the kit 2 or 4 (6.5mm x 6.5mm) capture areas per slide 4992 55�m barcoded spots per capture area Each barcoded spot contains millions of capture oligos 100 �m center-to-center distance between spots Highly sensitive on a variety of tissue types 3' HT & 3' LT & 5' HT & Fixed Single Cell Salient Characteristics - Chromium Next GEM Single Cell Fixed RNA The Chromium Next GEM Single Cell Fixed RNA Reagent Kits enables measurements of single cell gene expression in fixed human or mouse samples. Fresh human or mouse samples are fixed with paraformaldehyde to preserve biological states at collection and enable short- or long-term storage and transport Batch process and multiplex samples to improve operational efficiency and reduce experimental variability Scale single cell studies by multiplexing up to 16 samples and 128,000 cells per channel, for up to 128 samples and >1,000,000 cells per run Deeply interrogate cell types and states with simultaneous gene and cell surface protein expression Nuclei Isolation Salient Character tics - Chromium Nuclei Isolation The Chromium Nuclei Isolation Kit is an all-in-one solution for the standardized isolation of nuclei from frozen tissue for use in 10x Genomics Single Cell assays. Easily isolate nuclei from 3-5mg of frozen tissues (up to 8 in parallel) in an hour with little to no sample preparation optimization A unified workflow for a wide range of tissues that simplifies sample processing Characterize the heterogeneity of tissues more completely by preserving cells often lost during fresh tissue dissociation Use reliable, standardized reagents designed for 10x Genomics single cell sequencing assays Xenium spatial 2, 4, or 16 sample gene panel kits available Fully custom panels from 50 to 480 genes Pre-defined brain panels for human and mouse Add on panels available for 50 or 100 genes Advanced panels for specific transcripts Slides, reagents and consumables include all that is needed to run the experiment with any panel. The equipment shall be compatible with the following existing 10X Genomics Equipment CC = Chromium Connect iX = Chromium iX X = Chromium X Visium CytAssist Xenium Analyzer Delivery: The subsequent delivery orders will be issued for ongoing deliveries. Delivery orders may include options for extending the task order and/or additional quantities. Delivery of items in stock shall be shipped overnight or as specified in the resultant delivery orders. If an item is backordered, the contractor will notify NIA within 2 business days of the order being placed. All deliveries required under this contract shall be packaged, marked, and shipped in accordance with Government specifications. At a minimum, all deliverables shall be marked with the contract number and Contractor name and NIA customer address. The Contractor shall guarantee that all required materials shall be delivered in immediate usable and acceptable condition. (vii)����� The Government anticipates award of a firm fixed-price Indefinite Delivery Indefinite Quantity (IDIQ) contract for this acquisition, and the anticipated ordering period will be July 1, 2024-June 30, 2029. The ceiling for this IDIQ shall be $7,000,000. Delivery orders will be issued as necessary. Delivery will be f.o.b. destination. (viii)���� The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses:� https://www.acquisition.gov/browse/index/far �� https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html �� (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7, System for Award Management (Oct 2018) FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020) FAR 52.204-29, Federal Acquisition Supply Chain Security Act Orders � Representation and Disclosures (Dec 2023) FAR 52.211-6, Brand Name or Equal (Aug 1999) FAR 52.212-1, Instructions to Offerors-Commercial Items (Sep 2023) FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (Feb 2024) FAR 52.225-2, Buy American Certificate (Feb 2021) HHSAR 352.239-73, Electronic and Information Technology Accessibility Notice (December 18, 2015) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far ���� https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html � (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13, System for Award Management Maintenance (Oct 2018) FAR 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020) FAR 52.212-4, Contract Terms and Conditions--Commercial Items (Nov 2023). Addendum to this FAR clause applies to this acquisition and is attached. HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015) HHSAR 352.239-74, Electronic and Information Technology Accessibility (December 18, 2015) The following provisions and clauses apply to this acquisition and are attached in full text.� Offerors MUST complete the provisions at 52.204-24 and 52.204-26 and submit completed copies as separate documents with their proposal. FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Nov 2021) FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (Oct 2020) FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders--Commercial Products and Commercial Services (Feb 2024) Pricing Template Terms and Conditions for IDIQ Contracts SBCX Industry Subcontracting Guide NIH Invoice and Payment Provisions (ix)������ The Government will evaluate quotations or offers in accordance with FAR 13.106-2 and award a purchase order from this solicitation to the responsible offeror whose quote conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate quotes: a. Technical capability of the item offered to meet the Government requirement; b. Price; and c. Past performance [see FAR 13.106-2(b)(3)]. Technical and past performance, when combined, are significantly more important than cost or price. A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer�s specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (x)������� Offerors must include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items (Feb 2024), with its offer. If the offeror has completed FAR clause 52.212-3 at www.sam.gov, then the offeror does not need to provide a completed copy with its offer. (xi)������ In accordance with FAR 19.704 and FAR Clause 52.219-9, the submission of a subcontracting plan by other than small business offeror(s) is a requirement as a part of the proposal submission process and is to be submitted separately from the technical and cost proposals. An offeror's subcontracting plan must be determined to be acceptable, by the Contracting Officer, prior to the contract award. Offerors are required to submit a subcontracting plan electronically using the US Department of Health and Human Services (HHS) Small Business Customer Experience (SBCX) system via the link below: https://osdbu.hhs.gov/subcontracting/9467eb5a-195d-45ab-ba96-733e6a81779f The official point of receipt for determining timely submission of an offeror's subcontracting plan is the SBCX system and/or email notification. Once the subcontracting plan is successfully submitted in the SBCX system the offeror should receive an email notification and confirmation message of completion upon submission. If an offeror's subcontracting plan is not confirmed as received within the SBCX system by the proposal submission date specified in the solicitation, it will be considered late. Disposition of late submittals of a subcontracting plan by an offeror via the SBCX system is at the discretion of the Contracting Officer. See attached document �SBCX Industry Subcontracting Guide� for additional information. (xii)����� The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xiii)���� Responses to this solicitation must include sufficient information to establish the interested parties� bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s), product description, and any other information or factors that may be considered in the award decision. Such factors may include: past performance, special features required for effective program performance, trade-in considerations, probable life of the item selected as compared with that of a comparable item, warranty considerations, maintenance availability, and environmental and energy efficiency considerations. Offerors are required to provide the items listed above, but may also propose additional items for consideration by the Government. The attached Pricing Template should be used to provide a price quote. Respondents proposing on an equal product of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order.� The Unique Entity ID from SAM.gov, the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All quotations must be received by 11:00 A.M. Eastern, on May 31, 2024. and reference Solicitation Number 75N95024Q00161. Questions may be submitted electronically to Hashim Dasti, Contract Specialist, at hashim.dasti@nih.gov Fax responses will not be accepted.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/c29055f2b03d4e6cb81b45c5b78b1498/view)
- Place of Performance
- Address: USA
- Country: USA
- Country: USA
- Record
- SN07075764-F 20240525/240523230102 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |